SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, DSEY, ADAP, TCRR

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

If you are a Radius shareholder, click here to learn more about your rights and options .

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Friday, March 24, 2023

Information

Tags:

Sale, Diversey, Diversey Holdings, EQT, Advertising, Fraud, Therapy, Security (finance), Holding company, Solenis

Geotags:

NEW YORK, NY, US

⚠ partially generated by AI ↴

Organisation:

HALPER SADEH, HALPER SADEH LLC, DIVERSEY, TCR2 THERAPEUTICS

Stock Symbol:

Summary

Key Points:

If you are a Radius shareholder, click here to learn more about your rights and options .
If you are a Diversey shareholder, click here to learn more about your rights and options .
Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Radius Global Infrastructure, Inc. (NASDAQ: RADI)’s sale to EQT Active Core Infrastructure and Public Sector Pension Investment Board for $15.00 per share in cash. If you are a Radius shareholder, click here to learn more about your rights and options.

Diversey Holdings, Ltd. (NASDAQ: DSEY)’s sale to Solenis for $8.40 per share in cash. If you are a Diversey shareholder, click here to learn more about your rights and options.

Adaptimmune Therapeutics plc (NASDAQ: ADAP)’s merger with TCR² Therapeutics Inc. Under the terms of the agreement, TCR² stockholders will receive 1.5117 Adaptimmune ADS for each TCR² share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company. If you are a Adaptimmune shareholder, click here to learn more about your rights and options.

TCR² Therapeutics Inc. (NASDAQ: TCRR)’s sale to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR² share is fair to TCR² shareholders. Following the closing of the transaction, TCR² stockholders will own approximately 25% of the combined company. If you are a TCR² shareholder, click here to learn more about your rights and options.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com